Provided by Tiger Fintech (Singapore) Pte. Ltd.

Theriva Biologics

0.5020
+0.03196.79%
Post-market: 0.4925-0.0095-1.89%19:15 EDT
Volume:440.87K
Turnover:216.28K
Market Cap:4.55M
PE:-0.03
High:0.5100
Open:0.4705
Low:0.4653
Close:0.4701
Loading ...

Theriva Biologics Announces At-The-Market Stock Offering

TIPRANKS
·
21 Jun

Theriva Biologics Inc. Files Prospectus for Offering Up to $2.5 Million in Common Stock

Reuters
·
21 Jun

BRIEF-Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025

Reuters
·
27 May

Theriva™ Biologics Announces Presentation of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial at Asco 2025 and Investigator Meeting to Review Topline Data From the Virage Phase 2B Trial of Vcn-01 in Metastatic Pancreatic Cancer

THOMSON REUTERS
·
27 May

Theriva Biologics Q1 EPS $(1.55) Up From $(7.53) YoY

Benzinga
·
14 May

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

THOMSON REUTERS
·
14 May

Press Release: Theriva(TM) Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

Dow Jones
·
14 May

Theriva Biologics - Extending Its Cash Runway Into First Quarter of 2026

THOMSON REUTERS
·
14 May

Theriva Biologics Q1 2025: Reports Significant Changes in Revenue and Net Income, EPS Adjusts Accordingly

Reuters
·
14 May

Theriva Biologics Announces Closing of $7.5 Million Public Offering

THOMSON REUTERS
·
09 May

Press Release: Theriva Biologics Announces Closing of $7.5 Million Public Offering

Dow Jones
·
09 May

Theriva Biologics Cut to Hold From Buy by Maxim Group

Dow Jones
·
08 May

Theriva Biologics Inc : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS
·
08 May

BRIEF-Theriva Biologics Announces Pricing Of $7.5 Million Public Offering

Reuters
·
07 May

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

THOMSON REUTERS
·
07 May

BUZZ-Theriva Biologics soars after cancer drug meets main goal in mid-stage trial

Reuters
·
07 May

BRIEF-Theriva Biologics Announces Primary Endpoints For Efficacy And Safety Achieved In VIRAGE Phase 2B Clinical Trial Of VCN-01 With Gemcitabine/NAB-Paclitaxel In Newly-Diagnosed Metastatic Pancreatic Cancer Patients

Reuters
·
07 May

Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in Virage Phase 2B Clinical Trial of Vcn-01 With Gemcitabine/Nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients

THOMSON REUTERS
·
07 May

Theriva Biologics Inc - Vcn-01 Receives Orphan Drug and Fast Track Designation

THOMSON REUTERS
·
07 May

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

GlobeNewswire
·
10 Apr